“La Médecine d’après, leçons du Covid 19”
In this essay, Michel Goldman discusses the lessons from the pandemic that should influence medicine as a whole. After tracing the evolution of anti-infective strategies, he explains […]
La Médecine d’après, leçons du Covid 19
In this essay, Michel Goldman discusses the lessons from the pandemic that should influence medicine as a whole. After tracing the evolution of anti-infective strategies, he explain […]
Financial Intermediation and the Funding of Biomedical Innovation: A Review by Andrew W. Lo and Richard T. Thakor
A key paper on financing biomedical innovation: link here.
Review of literature on financial intermediation in the process by which new medical therapeutics are financed, developed, and delivered. […]
International Conference – Decentralisation of health care : European experiences
DULBEA, Solidaris & CIRIEC – 16th of November – Dupréel Room (ULB Solbosch)
In collaboration with Solidaris and CIRIEC, the DULBEA is organising an international conference on the 16th of November 2022 […]
Register now to the Interdisciplinary Program
Registrations for the 8th edition of the Interdisciplinary Program is now open.
Full program will be available soon.
Please find all the information on our dedicated page: here […]
Article: Covid long: portrait du grand imitateur du 21e siècle
Le Pr Michel Goldman (Professeur émérite d’immunologie et président de l’Institut interdisciplinaire pour l’innovation en santé à l’ULB) vient de publier un article consacré au Covid long dans Frontiers […]
Quel intérêt pour le dosage des anticorps anti-Covid ?
Quel intérêt pour le dosage des anticorps anti-Covid ? Ci-dessous les réponses de Michel Goldman à Laurence Dardenne dans La Libre.
- Comment mesure-t-on le taux […]
Register now to the conference: Build tomorrow’s healthcare for all European citizen
Register now to the Round table of the HealthTech Innovation Days: “Build tomorrow’s healthcare for all European citizen”
The conference will take place on […]
Improving the innovation/access trade-off for rare diseases in the EU after Covid-19
Scientific progress in the treatment of rare diseases is both an opportunity to improve lives and a financial challenge given the high cost of therapies. As stressed by […]
Did a Famous Doctor’s COVID Shot Make His Cancer Worse?
A lifelong promoter of vaccines suspects he might be the rare, unfortunate exception. On September 22 of last year, Michel Goldman, a Belgian immunologist and one of Europe’s […]